Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide in COVID-19
NCT04374279Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bicalutamide in coronavirus disease 2019 (COVID-19), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Apr 2021; status: withdrawn.
02
Drugs
bicalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04374279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374279.